中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2009年
12期
92-94
,共3页
骨质疏松症%中药治疗%骨密度%临床研究
骨質疏鬆癥%中藥治療%骨密度%臨床研究
골질소송증%중약치료%골밀도%림상연구
Osteoporosis%Chinese medicine treatment%Bone mineral density%Clinical research
目的:探讨以健脾药为主的中药方剂对妇女绝经后骨质疏松症的影响.方法:对2004年6月～2006年6月收治的106例绝经后骨质疏松症患者,根据健脾为主,佐以补肾壮骨、活血通络为治疗原则的方药健脾补骨汤进行治疗,并观察患者BMD和E2的临床指标.结果:两组患者治疗后骨密度均有升高,与治疗前比较,治疗组与对照组的BMD提高具有统计学意义(P<0.05).治疗组治疗前后E2差异有统计学意义,对照组治疗前后E2差异有统计学意义(P<0.05).结论:祖国医药在防治绝经后骨质疏松症方面疗效肯定,并在临床上有西药无法取代的优势.
目的:探討以健脾藥為主的中藥方劑對婦女絕經後骨質疏鬆癥的影響.方法:對2004年6月～2006年6月收治的106例絕經後骨質疏鬆癥患者,根據健脾為主,佐以補腎壯骨、活血通絡為治療原則的方藥健脾補骨湯進行治療,併觀察患者BMD和E2的臨床指標.結果:兩組患者治療後骨密度均有升高,與治療前比較,治療組與對照組的BMD提高具有統計學意義(P<0.05).治療組治療前後E2差異有統計學意義,對照組治療前後E2差異有統計學意義(P<0.05).結論:祖國醫藥在防治絕經後骨質疏鬆癥方麵療效肯定,併在臨床上有西藥無法取代的優勢.
목적:탐토이건비약위주적중약방제대부녀절경후골질소송증적영향.방법:대2004년6월～2006년6월수치적106례절경후골질소송증환자,근거건비위주,좌이보신장골、활혈통락위치료원칙적방약건비보골탕진행치료,병관찰환자BMD화E2적림상지표.결과:량조환자치료후골밀도균유승고,여치료전비교,치료조여대조조적BMD제고구유통계학의의(P<0.05).치료조치료전후E2차이유통계학의의,대조조치료전후E2차이유통계학의의(P<0.05).결론:조국의약재방치절경후골질소송증방면료효긍정,병재림상상유서약무법취대적우세.
Objective: To explore Jianpi prescription drugs based on traditional chinese medicine in postmenopausal wom-en the effects of osteoporosis. Methods: Since June 2004 to June 2006 106 cases of postmenopausal osteoporosis patients were treated, in Jianpi Bushen Zhuanggu, Huoxue Tongluo principles Jianpi fill prescriptions BMD and E2 were observed in patients with clinical indicators. Results: Bone mineral density after treatmentm in both groups were higher compared with pre-treatment, the diffirence statistical significance (P<0.05). Treatment group was different in the control group, in E2 there was also difference between before and after treatment (P<0.05). Conclusion: In prevention and treatment of postmenopansal osteoporosis, the effect of Chinese medicine is positive, and the advantages can not be replaced of West-ern medicine.
